Wednesday, 18 November 2026NewsWorldBusinessTech
Latest

Royal Marsden Study Finds Pre-SBRT ctDNA Predicts Earlier Progression

“These findings suggest that a simple blood test could give us valuable additional information about how advanced prostate cancer is behaving, beyond what we can see on scans,” said Alison Tree, consultant clinical oncologist at The Royal Marsden NHS Foundation Trust and chief investigator of the TRAP trial.

Researchers from The Royal Marsden, The Institute of Cancer Research and University College London found that measuring circulating tumor DNA (ctDNA) before stereotactic body radiotherapy (SBRT) helped identify which men with oligoprogressive, castration-resistant prostate cancer (CRPC) were likely to have longer disease control. The results were published November 11 in JAMA Network Open.

“We found that men with no detectable ctDNA before radiotherapy tended to have longer periods without their cancer progressing than those with detectable levels.” Alison Tree, consultant clinical oncologist at The Royal Marsden NHS Foundation Trust and chief investigator of the TRAP trial, said.

The phase 2 prospective, single-arm, nonrandomized clinical TRAP (Targeted Radiotherapy in Androgen-Suppressed Prostate Cancer Patients) trial evaluated SBRT to treat 81 patients with castration-resistant prostate cancer (CRPC) and 2 or fewer metastases and imaging evidence of progression while receiving an androgen receptor pathway inhibitor (ARPI). Between October 17, 2018, and February 1, 2023, the trial evaluated SBRT to treat 81 patients.

Blood samples collected before radiotherapy were tested centrally with PCF_SELECT, a next-generation sequencing assay that detects ctDNA through tumor-specific copy number changes. Neither patients nor clinicians knew the ctDNA results at the time of treatment. Data were collected prospectively using electronic trial case report forms and extracted on November 26, 2025.

Of 77 patients with evaluable samples, 19 (24.7%) had detectable ctDNA and 58 did not. Median follow-up was 24.5 months (IQR, 23.7–36.3). The difference in progression-free survival was pronounced: men with no detectable ctDNA had a median PFS of 7.8 months (95% CI, 5.9–11.4) versus 3.0 months (95% CI, 2.7–5.9) for those with detectable ctDNA (log-rank P = .003).

At six months, 58.3% of ctDNA-negative patients remained progression-free compared with 21.1% of ctDNA-positive patients (95% CI, 44.5%–69.8% vs 6.6%–41.0%). The primary end point was time from final SBRT to progression, defined as a PSA increase of 25% or greater from the post-SBRT nadir, radiologic or symptomatic progression, clinician decision to stop ARPI, or death from any cause.

Time to next therapy or death also favored the ctDNA-negative group: 29.6 months (95% CI, 17.8–37.6) versus 15.3 months (95% CI, 4.7–26.0), though the difference was not statistically significant after multivariable adjustment (adjusted HR 1.57; 95% CI, 0.78–3.14; P = 0.20). Overall survival showed a similar trend — 33.6 months (95% CI, 28.4–38.2) versus 27.2 months (95% CI, 19.2–not estimable) — but ctDNA status was not significantly associated with OS (adjusted HR 2.24; 95% CI, 0.93–5.42; P = 0.07). The primary TRAP report previously showed low rates of grade 3 or higher toxicity.

“These findings suggest that radiotherapy may be considered when ctDNA findings are negative; when ctDNA is detected, an alternative systemic treatment should be used” Gerhardt Attard, corresponding author, MD, PhD, FRCP, John Black Charitable Foundation Endowed Chair in Urological Cancer Research and director of the University College London (UCL) Cancer Institute, wrote in the publication with study coinvestigators.

What the findings suggest for practice

“Having a blood-based marker that aids us in determining for whom this is an appropriate approach is extremely helpful. It allows those that will benefit to continue abiraterone and enzalutamide and have SBRT alongside, whereas for others, the right approach might be to move on to a new medication for their prostate cancer,” said Alison Reid, consultant medical oncologist at The Royal Marsden NHS Foundation Trust and first author of the study.

The investigators said that patients rarely progressed at SBRT-treated sites, suggesting that earlier relapse in ctDNA-positive patients may reflect active metastases missed by imaging.

This contrasts with the ORIOLE trial (NCT02680587) in oligometastatic hormone-sensitive prostate cancer, where ctDNA was not associated with progression after SBRT — a difference the authors attributed to disease setting or assay sensitivity. The TRAP trial was sponsored by The Royal Marsden NHS Foundation Trust and conducted at eight sites in the UK.

Analysis limited by nonrandomized design and few PFS events

The analysis was a prespecified secondary endpoint without a predefined sample size for the ctDNA subgroup, and the limited number of PFS events constrained multivariable modeling. Because the trial was nonrandomized, the authors could not distinguish whether ctDNA is a prognostic or predictive biomarker. Further research is needed before ctDNA testing can be used to guide treatment decisions in routine practice. The study is registered at ClinicalTrials.gov (Identifier: NCT03644303).

Tony Sparrow, 73, a trial participant from Epsom, described the treatment as “absolutely fine. Just 10 minutes a session, completely painless and most importantly it did the trick—afterward there was nothing on the scan. There weren’t really any side effects either.”